32 results about "Renal Failures" patented technology

This invention belongs to the field of pharmaceutical analysis, specifically relating to a method for constructing a fingerprint spectrum of Shenfushu granules. The method for constructing a fingerprint spectrum of Shenfushu granules provided by this invention features high accuracy, high stability, good repeatability, good specificity, and strong specificity. The fingerprint spectrum analysis method for Shenfushu granules, a traditional Chinese medicine preparation for treating chronic renal failure, established by this invention can not only qualitatively analyze and identify the seven chemical components contained in this preparation, but also simultaneously present the characteristic peaks of five traditional Chinese medicines in the prescription, achieving the goal of overall quality control of multiple medicinal ingredients.

The application discloses a Bifidobacterium longum subsp.longum strain for relieving pathological characteristics of mice with chronic kidney disease induced by adenine, and belongs to the technical fields of microorganisms and medicines.The application provides a biomarker combination related to end-stage renal disease of peritoneal dialysis, wherein the corresponding species abundance in the biomarker combination presents significant difference in matched healthy control population and peritoneal dialysis population, can effectively distinguish the end-stage renal disease population of peritoneal dialysis and the healthy population, and has high sensitivity and specificity.The application also provides a Bifidobacterium longum subsp.longum strain CCFM1375 capable of delaying the progression of renal failure, which can be used for preparing products for improving chronic kidney disease.

The present invention relates to an artificial intelligence model and an implementation method therefor, which are capable of selecting and extracting, from CT images of patients with IgA nephropathy, image features significant for prognostic prediction and applying same to a machine learning model to thereby predict, with high accuracy, the likelihood of the patients with IgA nephropathy progressing to end-stage renal failure within five years. The present invention provides a prognostic prediction model that rapidly predicts the prognosis of a patient without an invasive kidney biopsy, overcomes the limitations of conventional pathology diagnosis relying on invasive methods, and enables periodic prognostic evaluation with significantly improved reliability. In addition, the present invention is capable of precisely reflecting characteristics of each item and accurately predicting a clinical course of a patient, by combining various feature selection methods and binary classifiers for each item of mesangial hypercellularity (M), endothelial hypercellularity (E), segmental glomerulosclerosis (S), and tubular atrophy / interstitial fibrosis (T), which constitute a MEST score.

A medical device system includes renal failure therapy machines each including a memory. The renal failure therapy machines are communicatively coupled such that the memories collectively form a distributed database. The system also includes a logic implementer associated with each renal failure therapy machine. Each logic implementer is programmed to automatically access the distributed database, so that each renal failure therapy machine periodically delivers prescription input parameters and / or treatment output data to at least one of the other renal failure therapy machines, and retrieves prescription input parameters and / or treatment output data from at least one of the other renal failure therapy machines. One of the renal failure therapy machines is configured to create at least one treatment record trend from the treatment output data and to share the at least one treatment record trend with other renal failure therapy machines through the distributed database.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using as says that detect Chitinase-3-like protein 1 as diagnostic and prognostic biomarker assays in renal injuries.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube, and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the local disinfection.

The invention provides a peritoneal dialysis device for renal failure, and belongs to the technical field of peritoneal dialysis. Comprising a positioning disc, an in-vivo dialysis tube, an in-vitro dialysis tube and a buffering assembly, the in-vivo dialysis tube and the in-vitro dialysis tube are installed on the positioning disc, the buffering assembly is used for buffering traction force on the in-vitro dialysis tube, the buffering assembly is further used for supporting and positioning the in-vivo dialysis tube, and the buffering assembly is connected with the positioning disc and a positioning plate. By arranging the buffer assembly, the in-vivo dialysis tube can be plastically fixed, the phenomenon that the in-vivo dialysis tube deviates and floats upwards after being used in the body of a patient for a long time is prevented, the difficulty of peritoneal dialysis operation of the patient is reduced, redundant in-vitro dialysis tubes outside the body of the patient can be stored, and the in-vivo dialysis tube fixing device is convenient to use. When the extracorporeal dialysis tube is pulled, the buffering assembly can absorb and buffer the pulling force at the first time, the situation that the pulling force directly acts on the skin of a patient, and consequently the patient feels uncomfortable is avoided, and the safety of the peritoneal dialysis device in daily use is improved.

The invention belongs to the technical field of biological medicines, and particularly discloses a liposome containing a natural extract composition as well as a preparation method and application of the liposome. The method for preparing the liposome containing the natural extract composition comprises the following steps: S1, adding the grape, poria cocos and apple extract, cholesterol and lecithin into an organic solvent, heating, stirring and dissolving to obtain an organic phase; adding the soybean extract and the ginseng extract into ultrapure water, heating and stirring to obtain a water phase; and S2, slowly adding the organic phase into the water phase while stirring, continuing stirring and emulsifying, and removing the organic solvent by reduced pressure distillation to obtain a liposome suspension. And S3, filtering the suspension, adding a freeze-drying protective additive, and freeze-drying to obtain the liposome. The invention also covers the application of the liposome in treating renal failure. In the invention, through the combination of natural extracts and the combination of a specific composition and liposome administration, the components generate a synergistic effect, and the pharmaceutical composition has a remarkable treatment effect on renal failure, especially chronic renal failure.

An object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases compared to already known monotherapies. A further object of the present invention is to provide a combination of pharmaceutical active ingredients for treating cardiovascular diseases, particularly cardiac and renal failure, characterized by chronic sodium retention, which reduces patient mortality and / or morbidity. Another object of the present invention is to improve the treatment and / or prevention of cardiovascular and renal diseases by administering a combination comprising finerenone and an SGLT2 inhibitor. [Solution] The present invention relates to pharmaceutical compositions and combinations comprising finerenone or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof, and an SGLT2 inhibitor or its hydrate, solvate, or pharmaceutically acceptable salt or polymorph thereof. The combinations can be used for the treatment and / or prevention of cardiovascular and / or renal diseases in humans and other mammals.

An extracorporeal and drug delivery system includes a renal failure therapy machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including an effluent pump for pumping effluent from the blood filter, and at least one of a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flowrate, a predilution pump for pumping replacement fluid into the arterial line at a predilution flowrate, or a postdilution pump for pumping replacement fluid into the venous line at a postdilution flowrate; an infusion pump operable to deliver an intravenous (“IV”) drug to the patient; and a coordinating logic implementor configured to determine if a formulation adjustment should be made to the IV drug when a constituent of the IV drug exists in the dialysis fluid, the predilution replacement fluid, and / or the postdilution replacement fluid.

A renal failure blood therapy system includes a memory device storing a therapy target for a patient. The system also includes a processor configured to receive the therapy target for the patient, receive a desired solute concentration for the patient, and apply the therapy target and the desired solute concentration as inputs to an optimization routine. The processor is also configured to execute the optimization routine to determine at least one dialysis therapy prescription specifying at least a dialysis therapy duration, a dialysis therapy frequency, and at least one of a dialysis therapy blood flow rate or a dialysis therapy dialysate flow rate. The processor is further configured to display the at least one dialysis therapy prescription for confirmation or selection by a clinician and transmit the selected or confirmed dialysis therapy prescription to a dialysis machine for a subsequent dialysis treatment for the patient.

A renal failure therapy system includes a fresh dialysis fluid tube having a connector for connecting to a dialyzer, a spent dialysis fluid tube having a connector for connecting to the dialyzer, a dialysis fluid circuit including a fresh dialysis fluid line, a spent dialysis fluid line, at least one of (i) a first disinfection device positioned between the fresh dialysis fluid line and the fresh dialysis fluid tube, or (ii) a second disinfection device positioned between the spent dialysis fluid line and the spent dialysis fluid tube and recirculation circuitry extending to a first machine connector for mating with the connector of the fresh dialysis fluid tube during disinfection and a second machine connector for mating with the connector of the spent dialysis fluid tube during disinfection. The system also includes a control unit configured to cause the first and second disinfection devices to be energized during the disinfection.

The present invention provides an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce organ dysfunction or organ failure. In a preferred embodiment, the invention provides an anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in the treatment of a chronic or acute disease or acute condition in a patient to prevent or reduce renal dysfunction or renal failure or hepatic dysfunction or hepatic failure.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein moiety A, R1, and R2 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia- reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism- related disease and genetic disorder of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

The present application relates to a kind of wearable arteriovenous fistula blood flow noninvasive monitoring device, which is based on the principle of fluid heat transfer, and is a wireless wearable electronic device for noninvasive measurement of arteriovenous fistula blood flow of patients undergoing maintenance hemodialysis due to renal failure, comprising a top PDMS package (1), a back-end processing module (2), a middle PDMS partition package (4), a front-end test module (5) and a bottom PDMS package (6). Compared with the prior art, the present application fully utilizes the small and portable characteristics of wearable electronics, the low sensitivity of material thermodynamic properties to motion state and the time average effect, solves the problems of low measurement accuracy, inconvenience of carrying and easy to cause treatment delay of existing blood flow measurement equipment, and reduces the risk of fistula occlusion of hemodialysis patients.

An extracorporeal and drug delivery system includes: (i) a renal failure treatment machine operable with a blood filter in fluid communication with an arterial line and a venous line, the machine including: (a) an effluent pump for pumping effluent from the blood filter at an effluent flow rate; and at least one of: (b) a dialysis fluid pump for pumping dialysis fluid to the blood filter at a dialysis fluid flow rate; (c) a pre-dilution pump for pumping replacement fluid into the arterial line at a pre-dilution flow rate; or (d) a post-dilution pump for pumping replacement fluid into the venous line at a post-dilution flow rate; (ii) an infusion pump operable to deliver an intravenous ("IV") drug to a patient at an IV drug flow rate; and (iii) a coordination logic implementer configured to adjust the IV drug flow rate based on an amount of the IV drug removed via the effluent flow rate.

The invention provides a novel ferroptosis inhibitor as well as a preparation method and application thereof, and belongs to the technical field of chemical synthesis medicines. The invention synthesizes a compound shown in the formula I and having a good inhibition effect on ferroptosis, and the compound can be used for preparing a ferroptosis inhibitor. The compound can also be used for preparing medicines for treating diseases such as ischemia-reperfusion injury, drug-induced liver injury, acute kidney injury, renal failure, hepatic pulmonary fibrosis, neurodegenerative diseases, cerebral apoplexy, myocarditis, myocardial infarction, heart failure, arthritis, chronic atrophic gastritis and the like related to ferroptosis, and has a wide market prospect.

The application provides a traditional Chinese medicine composition for treating uremia and a preparation method thereof, and belongs to the technical field of traditional Chinese medicine compositions. The traditional Chinese medicine composition for treating uremia is prepared from raw materials and is characterized by kidney-tonifying, spleen-strengthening, qi-benefiting, turbidity-removing, dampness-removing and blood-stasis-removing, and is an effective medicine for treating chronic renal failure and is worth popularization and application.

This invention discloses an 8–18 nm covalently bonded pH-responsive biomass active pharmaceutical ingredient (API), its preparation method, and its applications. The API has a three-layer covalently bonded core-shell structure, is free of free small molecules, and exhibits excellent structural stability. It is prepared from bamboo-derived biomass raw materials such as modified bile acid-bamboo flavonoid cocrystal complex, modified bamboo polysaccharides, and galactose oligosaccharides. The product has a particle size of 8–18 nm, a PDI < 0.21, a Zeta potential of -8.0 to -11.0 mV, and possesses pH-targeted drug release characteristics within the renal lesion microenvironment. Under normal physiological conditions, the drug leakage rate is less than 3.2%, and the in vivo biodegradation rate exceeds 99.1% within 72 hours. It exhibits no tissue accumulation and high safety. This invention targets the common pathological features of renal oxidative stress, chronic inflammation, and immune dysregulation in viral renal failure and renal cancer, exerting therapeutic effects through antioxidant, anti-inflammatory, renal tubular barrier repair, and immune regulation mechanisms. This invention employs a room-temperature pure aqueous phase reaction combined with a two-stage ultrafiltration process, ensuring mild conditions, batch stability, and suitability for industrial mass production.

The application relates to application of protocatechuic acid as an inhibitor of a calcium ion channel, belongs to the field of medicine, and also provides use of protocatechuic acid in preparation of drugs for treating cardiovascular diseases, coronary heart disease, atherosclerosis, end-stage renal failure, nervous diseases, chronic pain, acute pain or inflammatory diseases, proves that the protocatechuic acid can inhibit the calcium ion channel, especially a TRPC ion channel, and expands the use of the protocatechuic acid.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C-X-C motif chemokine 6, and C-C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

The present invention relates to a pharmaceutical composition for preventing and treating renal failure, which comprises, as an active ingredient, a compound represented by formula I, an optical isomer thereof, or a pharmaceutically acceptable salt thereof; a method for preventing and treating renal failure using said compound; use of said compound for preventing and treating renal failure; and use of said compound in the manufacture of a medicament for preventing and treating renal failure.

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, (I) wherein cycle A, R1, R2, and R3 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, lung disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, iron toxicity, iron metabolism-related disease and genetic disorders of GPX4. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament and methods of prevention and / or treatment of such diseases.

The present invention discloses phenyl-substituted dihydronaphthyridine compounds a preparation therefor and a use thereof, and belongs to the technical field of medicine. The compounds disclosed in the present invention are represented by formula I, and can be used as a mineralocorticoid receptor antagonist for treating, preventing or alleviating aldosteronism hyperplasia, diabetic nephropathy, hypertension, heart failure (comprising chronic heart failure, etc.), sequelae of myocardial infarction, liver cirrhosis, renal failure, stroke and other diseases in patients.

The present invention provides novel 2,4-dinitrophenol (DNP) derivatives and their prodrugs as modulators of mitochondrial function. The invention also provides pharmaceutical compositions comprising the compounds of the present invention, and methods thereof, for the treatment of various diseases and disorders related to or associated with mitochondrial dysfunction (e.g., obesity, diabetes, insulin resistance, liver disease, heart failure or renal failure, neurodegenerative diseases, or age-related diseases).

The present invention relates to a compound of formula (I) or a stereoisomer, or tautomer, wherein R1, R2, R3, and R4 have the same meaning as that defined in the claims and the description. The present invention also relates to the use of such compounds for the prevention and / or treatment of a disease associated with ferroptosis and / or oxytosis such as liver disease, chronic kidney disease, ocular surface diseases, wound healing, multiple organ dysfunction syndrome, neurological disease, acute renal failure, ischemia-reperfusion injury, sepsis, prevention of transplant rejection, and iron metabolism-related disease. The present invention also provides pharmaceutical compositions comprising such compounds, as well as the use of the compounds as a medicament.

The invention relates to a daily ration feed for constructing a hyperuricemia animal model as well as a preparation method and application thereof, and the daily ration feed comprises the following components in percentage by mass: 30%-35% of corn, 10%-12% of wheat middling, 20%-25% of wheat, 10%-15% of soybean meal, 1%-2% of a high-fat substance, 2%-3% of a premix, 1%-2% of stone powder, 0.2%-0.3% of choline chloride, 0.9%-1.4% of feed-grade minerals, 4%-9% of soybean hulls, 1%-5% of chicken meal and 2%-3% of uric acid. The composition also comprises 0.05%-0.15% of a fusobacterium nucleatum subsp. Multiforme freeze-dried powder. According to the daily ration feed, different raw material combinations and inactivated fusobacterium nucleatum subsp.polymorpha are mixed to prepare the daily ration feed, a hyperuricemia mouse model is constructed through feed feeding, and the comprehensiveness and stability of model pathological characteristics are improved through exogenous uric acid supplementation and a fusobacterium nucleatum subsp.polymorpha inflammation regulation and uric acid axis mode; the method has the advantages that mouse stress is reduced, operation is simpler and more convenient, the built hyperuricemia mouse model is higher in modeling rate, the model is more stable and safer, the modeling process is quicker, and the health problems such as renal failure metabolism can be effectively avoided in the modeling process.

The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, renal failure, hyponatremia, resistant edema, narcolepsy, hypertension, congestive heart failure, postoperative ocular hypotonia, sleep disorders, and pain.

The invention belongs to the technical field of biomedicine and regenerative medicine, and particularly relates to tissue gel with a kidney tissue endocrine recovery function and a preparation method of the tissue gel. The tissue gel is formed by mixing a renal cortex tissue in a hydrogel matrix material; the mass ratio of the hydrogel matrix material to the renal cortex tissue is (1-10): 1; preferably, the hydrogel matrix material is selected from one or a mixture of more than two of sodium alginate, gelatin, hyaluronic acid, collagen, fibrin, polyethylene glycol and polylactic acid-glycolic acid copolymer. The tissue gel disclosed by the invention realizes long-term survival and functional reconstruction of ectopic kidney tissues in the spleen, has the characteristics of simplicity and convenience in operation, high success rate and large clinical transformation potential, and can provide a new treatment strategy for renal failure and endocrine defect diseases.

The invention discloses an insulated electrode for pulsed electric field ablation for arrhythmia treatment, relates to the field of pulsed electric field ablation, is an improvement of a common electrode, can be applied to an existing field ablation electrode catheter, and provides an insulated electrode for pulsed electric field ablation for arrhythmia treatment. The insulating layer is arranged on the outer surface of the electrode on the catheter, so that blood coagulation, hemolysis and gas explosion caused by heat generated by current directly flowing through blood can be greatly reduced, and complications such as myocardial infarction, cerebral infarction or renal failure caused by the blood coagulation, hemolysis and gas explosion can be greatly reduced; the improvement has the characteristics that the cost is low, the yield is high, the popularization is easy, the shape and the structure of the original ablation electrode are not changed, the use is convenient, meaningless thermal ablation during ablation is greatly reduced, real pulsed electric field ablation is realized, and the occurrence of atrial esophageal fistula and phrenic nerve injury are reduced.